Low-dose aspirin-associated upper gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulcers

BMC Research Notes

Kunio Kasugai¹  Yasushi Funaki¹  Naotaka Ogasawara¹  Mari Mizuno¹  Akihito Iida¹  Makoto Sasaki¹  Yoshitsugu Ito¹  Naohiko Kawamura¹ 

[1] Department of Gastroenterology, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute, Aichi 480-1195, Japan

关键词: Risk factor;    Proton pump inhibitors;    Primary prevention;    Peptic ulcer;    Low-dose aspirin;   

Others  :  1140871
DOI  :  10.1186/1756-0500-6-455

 received in 2012-11-29, accepted in 2013-11-08,  发布年份 2013

【 摘 要 】

Background

Long-term administration of low-dose aspirin (LDA) is associated with a greater risk of adverse events, including gastroduodenal ulcers. The purpose of this study was to identify the risk factors for and assess the role of medication use in the development of peptic ulcer disease in Japanese patients with no history of peptic ulcers.

Methods

Consecutive outpatients receiving LDA (75 mg/day) who underwent esophagogastroduodenoscopy between January and December 2010 were enrolled. Clinical parameters, peptic ulcer history, concomitant drugs, the presence of Helicobacter pylori infection, reason for endoscopy, and endoscopic findings were analysed.

Results

Of 226 total patients, 14 (6.2%) were endoscopically diagnosed with peptic ulcer. Age, sex, current smoking status, current alcohol consumption, endoscopic gastric mucosal atrophy, and abdominal symptoms were not significantly associated with peptic ulcers. Diabetes mellitus was more frequent (42.9% vs. 16.5%; P = 0.024) in patients with peptic ulcers than in those without peptic ulcers. Using multiple logistic regression analysis, co-treatment with anticoagulants or proton pump inhibitors (PPIs) was significantly associated with increased and decreased risk for peptic ulcer, respectively (odds ratio [OR], 5.88; 95% confidence interval [CI], 1.19 − 28.99; P = 0.03 and OR, 0.13; 95% CI, 0.02 − 0.73; P = 0.02, respectively). Co-treatment with additional antiplatelet agents, H₂-receptor antagonists, angiotensin II Type 1 receptor blockers, angiotensin-converting enzyme inhibitor, 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, or nonsteroidal anti-inflammatory drugs was not associated with peptic ulcer development.

Conclusion

The use of PPIs reduces the risk of developing gastric or duodenal ulcers in Japanese patients taking LDA without pre-existing gastroduodenal ulcers. However, this risk is significantly increased in both patients ingesting anticoagulants and patients with diabetes. These results may help identify patients who require intensive prophylaxis against aspirin-induced peptic ulcers.

【 授权许可】

   
2013 Kawamura et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS: Long-term aspirin use and mortality in women. Arch Intern Med 2007, 167:562-572.
• [2]Cryer B, Feldman M: Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999, 117:17-25.
• [3]Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ: Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001, 52:563-571.
• [4]Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J, Sanz M, Montoro M, Sainz R: Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000, 343:834-839.
• [5]Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida Y, Tsukui T, Osawa H, Sakurai Y, Yoshino J, et al.: Case-control study on the association of upper gastrointestinal bleeding and Nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 2006, 62:765-772.
• [6]Laine L: Approaches to Nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120:594-606.
• [7]Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, Rodrigo L, Balanzo J, Bajador E, Almela P, et al.: A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with Nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005, 100:1685-1693.
• [8]Moukarbel GV, Signorovitch JE, Pfeffer MA, McMurray JJ, White HD, Maggioni AP, Velazquez EJ, Califf RM, Scheiman JM, Solomon SD: Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J 2009, 30:2226-2232.
• [9]Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND: Omeprazole compared with misoprostol for ulcers associated with Nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998, 338:727-734.
• [10]Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ: A comparison of omeprazole with ranitidine for ulcers associated with Nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998, 338:719-726.
• [11]Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, et al.: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344:967-973.
• [12]Yeomans N, Lanas A, Labenz J, van Zanten SV, van Rensburg C, Racz I, Tchernev K, Karamanolis D, Roda E, Hawkey C, et al.: Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008, 103:2465-2473.
• [13]Kimura T, Takemot T: An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969, 1:87-97.
• [14]Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R: Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002, 16:779-786.
• [15]Chan FK: Review: low-dose aspirin causes a small increase in gastrointestinal bleeding. ACP J Club 2007, 146:13.
• [16]Malfertheiner P, Chan FK, McColl KE: Peptic ulcer disease. Lancet 2009, 374:1449-1461.
• [17]Taha AS, McCloskey C, Prasad R, Bezlyak V: Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:119-125.